Mydecine Innovations Group Inc.
MYCO
CNSX
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 1.24M | 1.62M | 1.81M | 2.63M | 2.86M |
Depreciation & Amortization | -- | -- | -- | 0.00 | 900.00 |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 182.50K | 1.66M | 1.86M | 5.13M | 4.59M |
Operating Income | -182.50K | -1.66M | -1.86M | -5.13M | -4.59M |
Income Before Tax | 125.30K | -1.82M | -2.36M | -9.15M | -8.57M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | 0.13 | -1.82 | -2.36 | -9.15 | -8.57 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 125.30K | -1.82M | -2.36M | -9.15M | -8.57M |
EBIT | -182.50K | -1.66M | -1.86M | -5.13M | -4.59M |
EBITDA | 255.60K | -1.39M | -1.85M | -5.12M | -4.58M |
EPS Basic | 0.00 | -0.03 | -0.04 | -0.17 | -0.18 |
Normalized Basic EPS | -0.01 | -0.03 | -0.03 | -0.11 | -0.11 |
EPS Diluted | 0.00 | -0.03 | -0.04 | -0.17 | -0.18 |
Normalized Diluted EPS | -0.01 | -0.03 | -0.03 | -0.11 | -0.11 |
Average Basic Shares Outstanding | 246.90M | 246.33M | 238.38M | 226.21M | 193.21M |
Average Diluted Shares Outstanding | 246.90M | 246.33M | 238.38M | 226.21M | 193.21M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |